Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.

Khaddour, Karam; Chicoine, Michael R; Huang, Jiayi; Dahiya, Sonika; Ansstas, George

Khaddour, Karam; Chicoine, Michael R; Huang, Jiayi; Dahiya, Sonika; Ansstas, George.

Affiliation

Khaddour K; 1Division of Medical Oncology, Department of Medicine.
Chicoine MR; 2Department of Neurologic Surgery.
Huang J; 3Department of Radiation Oncology, and.
Dahiya S; 4Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
Ansstas G; 1Division of Medical Oncology, Department of Medicine.

J Natl Compr Canc Netw ; 18(12): 1590-1595, 2020 12.

Article in En | MEDLINE | ID: mdl-33285519

Subject(s)

Craniopharyngioma; Pituitary Neoplasms; Craniopharyngioma/drug therapy; Craniopharyngioma/genetics; Humans; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoadjuvant Therapy; Pituitary Neoplasms/drug therapy; Pituitary Neoplasms/genetics; Protein Kinase Inhibitors/therapeutic use; Proto-Oncogene Proteins B-raf/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Craniopharyngioma Limits: Humans Language: En Journal: J Natl Compr Canc Netw Journal subject: NEOPLASIAS Year: 2020 Type: Article

Fulltext

XML

PubMed Links

Search on Google